The STRIVE Study: Development of a Blood Test for Early Detection of Multiple Cancer Types

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

99481 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-02-28

Study Completion Date

2024-04-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

GRAIL is using high-intensity sequencing of circulating cell-free nucleic acids (cfNAs) to develop blood tests to detect cancer early. The purpose of this study is to validate the ability of the pre-specified GRAIL Test to detect breast cancer and other invasive cancers, including hematologic malignancies, that will occur within one year of the first study blood draw.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Circulating Cell-free Genome Atlas Study

NCT02889978

Neoplasms Cancer

UNKNOWN

Genomic Profiling in Recommending Treatment for Patients With Metastatic Solid Tumors

NCT02215928

Unspecified Adult Solid Tumor, Protocol Specific

RECRUITING

Genetic & Pathological Studies of BRCA1/BRCA2: Associated Tumors & Blood Samples

NCT01034033

Breast Cancer Ovarian Cancer Gynecologic Cancers +1 more

RECRUITING

Non-invasive Liquid Biopsy Analysis of Epigenomics Signatures in Multiple Cancer Types

NCT03869814

Diagnosis of Cancer of Various Organs

UNKNOWN

Validation of a Multi-gene Test for Lung Cancer Risk

NCT01130285

Lung Cancer

ACTIVE_NOT_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Detection of early stage cancer may be possible through analysis of circulating cell-free nucleic acids (cfNAs) shed into the blood by tumors. GRAIL is using high-intensity sequencing (based on broad genomic coverage and deep sequencing) of cfNAs, combined with machine learning, to develop blood tests to detect cancer early. The purpose of this prospective, multi-center, observational cohort study is to validate an assay for the early detection of breast cancer and other invasive cancers, including hematologic malignancies. The study will collect blood samples from participants within 28 days of their screening mammogram. Additional blood samples will also be collected for a subset of participants. For participants who receive a cancer diagnosis during the study, archival tissue samples will be collected.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neoplasms Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Prospective Cohort

This is a prospectively enrolling cohort study with a pre-specified molecular analysis plan. A stratified case-cohort design will be employed to select cancer cases and non-cancer subjects who will be assayed. All cases of cancer (breast and non-breast cancer) will be selected. A random subset of the overall study cohort will also be selected.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Women undergoing mammography for screening indications or have an appointment for screening mammography.
2. Participant provides informed consent and expresses understanding of the protocol and its requirements, risks, and discomforts.